Nifty Next 50Healthcarenifty next 50
Zydus Lifesciences Share Price & Analysis
Zydus Lifesciences is a research-led pharma company with strengths in generics, vaccines, and wellness.
Live price
ZYDUSLIFE · Healthcare
₹1,178.30
+5.40 (+0.46%)
Day High
₹1,181.00
Day Low
₹1,155.90
52W High
₹1,232.10
52W Low
₹835.50
Volume today: 2.12 L
Key fundamentals
Market cap
—
P/E ratio
—
P/B ratio
—
ROE
—
Debt / Equity
—
Dividend yield
—
Revenue growth
—
Earnings growth
—
Live fundamentals from Yahoo Finance where available. Reference ratios may lag the latest quarterly results.
PaisaTamil Consensus
HOLDScore 50/100 · Low confidence
Mixed signals across valuation and momentum. Existing investors may hold; new entries should wait for clarity.
12M Price Target
₹1,214
Low ₹1,072 · High ₹1,390
Analyst-style Breakdown
Strong Buy
0
Buy
0
Hold
28
Sell
0
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum75/100
1M -3.5%, 1Y +15.8%
Earnings Trend25/100
Latest quarter revenue ₹7.8k Cr, profit ₹940 Cr
Valuation50/100
P/E — vs sector median ~35x
Financial Quality28/100
ROE —, ROCE —
Technical Position72/100
Trading between 52W low 836 and high 1232
Modelled from public market signals — not live broker analyst data. For education only; not SEBI-registered investment advice.
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Jun 2026 | ₹7.8k Cr | ₹940 Cr | ₹9.35 | +24.0% | -19.7% |
| Mar 2026 | ₹7.4k Cr | ₹1.3k Cr | ₹12.65 | — | — |
| Dec 2025 | ₹6.8k Cr | ₹1.0k Cr | ₹10.36 | — | — |
| Jun 2025 | ₹6.5k Cr | ₹1.5k Cr | ₹14.58 | — | — |
| Mar 2025 | ₹6.3k Cr | ₹1.2k Cr | ₹11.64 | — | — |
Reference Ratios
Market Capⓘ
—
P/E Ratioⓘ
—
P/B Ratioⓘ
—
ROEⓘ
—
ROCEⓘ
—
Div Yieldⓘ
—
Company Overview
Manufactures and markets formulations in India, US, and emerging markets plus CDMO services.
Strengths
- + Diversified US and India revenue mix
- + Vaccine and complex generics pipeline
Risks
- − US pricing pressure in generics
- − FDA compliance at manufacturing facilities
Latest News
No recent news articles for Zydus Lifesciences yet. Check back after the next hourly scan.
Browse all market news →Investor Questions
Yes. Zydus Lifesciences is a current constituent of the Nifty Next 50, which represents the 50 largest Nifty 100 companies outside the Nifty 50.